Gene Integration in Antibody Production: Overcoming Challenges for Optimal Clone Selection

Clone Selection for Antibody Production

Importance of Clone Selection

Clone selection is a critical process in antibody production that involves isolating and identifying individual cells, or clones, that exhibit superior characteristics for producing the desired antibody. This process ensures that the selected clones can consistently produce high levels of antibodies with the necessary quality and stability required for therapeutic use.
During clone selection, cells are screened and evaluated based on several criteria, including productivity, genetic stability, and the ability to perform well in large-scale bioreactors. The goal is to select clones that not only produce high yields of antibodies but also maintain consistent expression and quality over time. This process typically involves advanced techniques such as high-throughput screening, automated systems, and single-cell cloning to efficiently identify the best-performing clones.
The process of clone selection involves isolating individual cells that demonstrate the highest productivity and stability. These cells are then expanded to produce large quantities of antibodies. The significance of this selection process lies in its direct influence on several key aspects of antibody production:

Yield:

High-yield clones are essential for producing sufficient quantities of antibodies to meet therapeutic needs. Selecting clones with superior productivity can significantly enhance the overall yield, making the production process more efficient and cost-effective.

Quality:

The quality of antibodies produced is paramount for their efficacy as therapeutic agents. Optimal clones must produce antibodies with proper folding, glycosylation, and other post-translational modifications that ensure their functionality and stability.

Stability:

Clonal stability is crucial for maintaining consistent antibody production over time. Genetically unstable clones can exhibit variability in antibody expression, leading to fluctuations in yield and quality. Stable clones ensure reliable and reproducible production processes, essential for large-scale manufacturing.
It is therefore important to use advanced techniques in clone selection to achieve these goals. For example, high-throughput analytical strategies and automated systems, such as Verified In-Situ Plate Seeding System VIPS to enable more efficient and accurate identification of optimal clones. These modern methods reduce the time and labor involved in traditional clone selection processes, enhancing overall productivity.

Understanding Gene Integration in Antibody Production

What is Gene Integration?

Gene integration in the context of antibody production refers to the process of inserting a specific antibody gene sequence into the genome of a host cell, thereby enabling the host to produce the desired antibody. This can be achieved through various methods, including viral vectors, plasmid-based systems, and more advanced gene-editing technologies.

Role of Gene Integration in Antibody Production

Stable integration of the antibody gene into the host cell genome is a critical aspect as it allows for continuous and consistent expression of the antibody. Unlike transient expression systems, where the gene of interest is introduced temporarily, stable gene integration allows for a long-term expression of the antibody genes. This stability is critical for commercial-scale production of therapeutic antibodies, as it ensures that the cells retain the ability to produce the antibody over an extended period.
Gene integration significantly influences clone selection, as it determines the stability and productivity of the resulting clones. During this process, the aim is to identify cell lines that can consistently produce high levels of the desired antibodies.

Stable Gene Integration for Reliable Clones:

Stable integration ensures that the gene of interest is integrated into the host genome, enabling a long-term and stable expression. This is vital for selecting clones that maintain consistent antibody production. Clones with unstable gene integration may lose the ability to produce the antibody or produce it at lower levels, making them unsuitable for commercial-scale production.

Impact on Clone Productivity:

The number of integrated gene copies can influence the level of antibody expression. Enhancing gene integration techniques to increase the number of copies can boost antibody yields, which is critical for identifying high-producing clones that meet therapeutic production requirements.

Selecting Clones for Scalability and Specificity:

Gene integration also allows for the customization of antibody production, enabling the development of clones that produce antibodies tailored to specific therapeutic needs. This customization is particularly valuable in personalized medicine, where specific antibodies are required to target unique antigens.

Advancements in Gene Integration and Clone Selection:

Recent technological advances, such as genomic barcoding and gene targeting, have improved the monitoring and control of clonal diversity. These innovations provide detailed insights into the genetic stability of each clone, facilitating the identification of optimal clones for production. For instance, genomic barcoding allows for the tracking of clonal diversity, optimizing antibody production, and ensuring that the selected clones are both highly productive and stable.

Overview of Gene Integration Types

Gene integration techniques can be broadly categorized into stable and transient integration, each serving different purposes in antibody production.

Stable Integration:

Stable integration involves the permanent insertion of the gene of interest into the host cell’s genome. This method ensures that the introduced gene is inherited by all daughter cells during cell division, allowing for continuous and consistent expression of the desired antibody. Stable integration is crucial for the commercial-scale production of therapeutic antibodies, as it supports long-term production and consistency in antibody quality. Techniques commonly used for stable integration include viral vectors, transposon-based systems, and CRISPR/Cas9. The main advantage of stable integration is its reliability in producing antibodies over an extended period, which is essential for manufacturing consistent therapeutic products.

Transient Integration:

Transient integration, on the other hand, involves the temporary introduction of the gene of interest into the host cells. In this case, the genetic material does not integrate into the host genome and is not passed on to progeny cells. As a result, the expression of the gene is short-lived, lasting only a few days to weeks, depending on the method used and the cell type. Transient integration is typically achieved through plasmid transfection or other non-integrative methods. This approach is useful for short-term studies, rapid protein production, and situations where stable expression is not required. The primary advantage of transient integration is the speed and simplicity of the process, making it suitable for preliminary experiments and testing.

Main Techniques for Gene Integration

Viral Vectors:

Viral vectors are commonly used to introduce genetic material into host cells. They leverage the natural ability of viruses to infect cells and integrate their genetic material into the host genome. Retroviruses and lentiviruses are frequently used due to their efficiency in integrating into the host genome. This method provides high efficiency of integration but raises concerns about insertional mutagenesis and potential oncogenicity.

Transposon-Based Systems:

Also known as “jumping genes,” transposons are DNA sequences that can change their position within the genome. These systems can pose a risk of insertional mutagenesis, where random insertions can disrupt essential genes or regulatory elements, leading to harmful mutations.

CRISPR/Cas9:

This system is a powerful gene-editing tool that allows for precise modifications in the genome. It can be used to create targeted double-strand breaks in the DNA, facilitating the integration of a gene at a specific location. This precision minimizes off-target effects and improves the stability of the inserted gene, making it a preferred method for therapeutic applications.

Recombinase-Mediated Cassette Exchange (RMCE):

RMCE is a technique that uses recombinases, enzymes that catalyze the exchange of DNA sequences at specific sites in the genome. This method allows for the precise replacement of a DNA segment with another, facilitating the integration of the gene of interest into a pre-determined location. RMCE is particularly useful for creating stable cell lines with consistent gene expression levels.

Homologous Recombination:

It is a naturally occurring process that can be harnessed to introduce genetic material into specific locations in the genome. By designing DNA sequences that are homologous to the target site, researchers can induce the integration of new genes into specific loci. This technique ensures precise integration but is generally less efficient compared to other methods.

Challenges in Gene Integration for Antibody Production

Efficiency of Gene Integration

Gene integration efficiency refers to the proportion of successfully integrated genetic material into the host cell genome relative to the total number of cells exposed to the integration process. It is a measure of how effectively a gene delivery system can insert the desired gene into the cellular genome, ensuring that the gene is stably maintained and expressed.
One of the primary challenges in gene integration is achieving high efficiency of gene delivery and stable integration into the host cell genome. This can be particularly problematic in systems where the integration event is rare or where the delivery mechanism is not highly effective. For instance, while CRISPR-based strategies offer high precision, the efficiency of integrating large genetic fragments can still be limited. Additionally, issues such as the immune response to viral vectors and the physical barriers in target tissues can further reduce the efficiency of genes.

Factors Affecting Integration Efficiency:

Vector Design and Delivery Method:

The choice of vector and delivery method significantly impacts integration efficiency. For example, viral vectors like lentivirus are more efficient at integrating into the host genome compared to non-viral methods like electroporation. However, issues such as vector immunogenicity and the limited packaging capacity of certain vectors (e.g., AAV) can limit their effectiveness (Adeno-associated virus engineering, IJN).

Cell Type and Condition:

The type of host cell and its physiological state play crucial roles in determining the efficiency of gene integration. Actively dividing cells are generally more conducive to gene integration compared to non-dividing cells. This is particularly true for retroviral vectors, which require cell division to facilitate the integration of the viral genome into the host DNA. During cell division, the nuclear envelope breaks down, providing retroviral vectors with access to the host genome, thereby enhancing the efficiency of integration. In contrast, non-dividing cells, present a significant barrier to gene integration, making it more challenging for vectors to access the host genome.

Gene Copy Number and Position:

The number of integrated gene copies and their genomic position are critical factors that can significantly influence both the expression levels and stability of the desired antibody. An increase in the number of integrated gene copies generally correlates with higher expression levels, as more templates are available for transcription. This can be particularly advantageous for achieving high yields of antibody production, which is essential for therapeutic applications.
However, there are potential downsides to increasing gene copy numbers. One major concern is the phenomenon of diminishing returns, where beyond a certain point, additional copies do not proportionally increase expression levels. This can occur due to factors such as cellular resource limitations or metabolic burden, where the cellular machinery becomes saturated, leading to inefficiencies.
Furthermore, high copy numbers can sometimes lead to undesirable effects, such as gene silencing or instability. Overexpression of the gene can trigger cellular stress responses or unintended interactions with other cellular components, potentially compromising cell viability and stability. Additionally, the random integration of multiple gene copies can result in insertion into sensitive genomic regions, which might disrupt essential genes or regulatory elements.

Stability of Gene Integration

The stability of gene integration refers to the ability of an integrated gene to remain consistently active and expressed over time without being lost or silenced. This stability is a critical factor in the production of therapeutic antibodies, as it ensures that the integrated gene continues to produce the desired antibody reliably and at consistent levels.
However, maintaining stable gene expression is challenging due to various factors that can lead to gene silencing. These issues can compromise the efficiency and reliability of antibody production processes, making it essential to address and manage them effectively.

Gene Silencing:

Gene silencing refers to the process by which an active gene becomes transcriptionally inactive. This can occur through several mechanisms, such as DNA methylation, histone modification, and the formation of heterochromatin. These epigenetic changes can alter the chromatin structure, making the integrated gene less accessible to the transcriptional machinery, thereby reducing or completely halting its expression. Gene silencing can occur spontaneously over time or be induced by external factors, such as stress conditions or changes in the cellular environment.

Clone Variability

Clone variability refers to the differences observed among individual clones derived from a single parent cell line, especially concerning gene expression levels, growth rates, and overall production characteristics. Understanding clone variability is essential for ensuring that the selected clones meet the stringent requirements for reliable and high-quality antibody production. Effective management of clone variability helps streamline the selection process, enabling the identification of clones that will perform consistently under large-scale production conditions.

Impact of Clone Variability on Antibody Production

The variability among clones can have several significant impacts on the production of therapeutic antibodies:

Inconsistent Product Quality:

Variations in gene expression levels and post-translational modifications among clones can lead to differences in the quality of produced antibodies. This can manifest as variability in glycosylation patterns, protein folding, and stability, which may affect the efficacy and safety of the therapeutic product.

Production Efficiency:

Clones with lower productivity can reduce the overall efficiency of the production process. The presence of non-productive or low-producing clones decreases the overall yield of antibodies, thereby increasing production costs and time.

Process Scalability and Reproducibility:

High clone variability can complicate the scaling-up process from laboratory-scale to industrial-scale production. Ensuring that selected clones maintain consistent performance across different scales is essential for achieving reproducibility and meeting regulatory requirements.

Regulatory Compliance:

Regulatory agencies demand consistent and high-quality production of therapeutic antibodies. Variability among clones can challenge these standards, potentially causing delays in approval or necessitating additional regulatory scrutiny.

Heterogeneity in Clones

Heterogeneity among clones arises from several sources, including genetic, epigenetic, and environmental factors. Despite originating from the same parent cell, individual clones can exhibit substantial differences in:

Gene Expression Levels:

Variations in the number of integrated gene copies, integration sites, and regulatory elements can lead to differences in the expression levels of the desired antibody. Some clones may produce high levels of antibodies, while others may have low or even negligible production.

Epigenetic Modifications:

Differences in DNA methylation patterns, histone modifications, and chromatin structure can result in varying levels of gene silencing or activation among clones. These epigenetic changes can be influenced by the cell culture environment and can lead to heterogeneity in gene expression.

Cellular Responses to Environmental Conditions:

Clones may respond differently to culture conditions, such as nutrient availability, oxygen levels, and pH. These environmental factors can affect cell growth, viability, and antibody production rates.

Regulatory Considerations

Regulatory agencies like the FDA and EMA require stringent evaluation of gene integration techniques to ensure safety and efficacy. This involves assessing risks such as off-target effects and insertional mutagenesis, and verifying the genetic stability of cell lines. Quality control measures are mandated to maintain consistency across production batches, including detailed documentation of all processes. Before approval, therapeutic antibodies must undergo rigorous clinical trials to demonstrate safety and efficacy, with all phases monitored closely by regulatory bodies.

Overcoming Challenges of Gene Integration for Optimal Clone Selection

Building on the previously discussed challenges in gene integration, it’s clear that overcoming these obstacles is vital for the successful selection of optimal clones in antibody production. The efficiency and stability of gene integration directly influence the quality and consistency of the resulting therapeutic antibodies. To tackle these challenges, this section delves into advanced strategies for enhancing gene integration efficiency and optimizing delivery methods. These approaches are crucial for selecting clones that can reliably produce high-quality antibodies, ensuring consistent performance in therapeutic applications.

Improving Gene Integration and Stability

Optimization of Vector Design

Strong Promoters and Enhancers:

Strong, constitutive promoters drive high levels of gene expression following integration. Enhancers further amplify transcription levels by boosting promoter activity. Common examples include the cytomegalovirus (CMV) promoter and the elongation factor-1 alpha (EF-1α) promoter.

Selectable Markers:

Selectable markers, such as antibiotic resistance genes or fluorescent proteins, facilitate the identification and selection of successfully transfected cells. This selective pressure ensures the survival and proliferation of cells with stable gene integration.

Codon Optimization:

Adjusting the coding sequence to match the host organism’s codon usage enhances translation efficiency and antibody expression. This optimization helps overcome potential bottlenecks in protein synthesis due to rare codon usage.

Self-Inactivating (SIN) Vectors:

SIN vectors have deletions in their long terminal repeats (LTRs), reducing the risk of activating oncogenes upon integration. This design feature enhances safety, particularly in clinical applications.

Use of Integration Enhancers

Small molecules and proteins that facilitate the integration process can enhance the efficiency of gene delivery and stable integration.

Histone Deacetylase Inhibitors (HDACi):

HDAC inhibitors, such as valproic acid or trichostatin A, prevent the deacetylation of histones, resulting in increased chromatin accessibility. This promotes the integration of exogenous DNA and enhances the transcriptional activity of the integrated gene

DNA Repair Modulators:

Modulating DNA repair pathways affects the efficiency of gene integration. Inhibiting non-homologous end joining (NHEJ) and promoting homologous recombination (HR) increase the precision and efficiency of gene integration, particularly in techniques like CRISPR/Cas9.

Epigenetic Modifiers:

Compounds that modify the epigenetic landscape, such as DNA methyltransferase inhibitors, help prevent gene silencing and promote sustained expression of integrated genes. These modifiers can help maintain an active chromatin state around the integration site.

Viral Integration Proteins:

In some viral vector systems, specific proteins can enhance the integration process. For instance, the use of integrase proteins in retroviral vectors can improve the efficiency and specificity of gene insertion into the host genome.

High-Fidelity Gene Editing Technologies

They are designed to introduce specific genetic changes at targeted locations within the genome while minimizing unintended alterations elsewhere. These technologies achieve higher accuracy by enhancing the specificity of the gene-editing components, thereby reducing the likelihood of off-target activity.

Examples of High-Fidelity Gene Editing Technologies

• CRISPR/Cas9 High-Fidelity Variants: The CRISPR/Cas9 system is a widely used gene-editing tool that utilizes a guide RNA (gRNA) to direct the Cas9 nuclease to specific DNA sequences. High-fidelity variants of Cas9, such as SpCas9-HF1 and eSpCas9, have been designed to reduce off-target effects by altering the Cas9 structure, thereby increasing its specificity. These variants ensure that gene editing occurs only at the intended target sites, making them ideal for therapeutic applications where precision is paramount.
• Base Editing: Base editing is a novel gene-editing technique that enables the direct conversion of one DNA base into another without creating double-strand breaks. This method offers an even higher level of precision, as it does not rely on the cellular DNA repair mechanisms that can introduce errors. Base editors, such as adenine base editors (ABEs) and cytosine base editors (CBEs), can precisely correct point mutations or introduce specific changes, making them valuable for correcting genetic defects or optimizing antibody genes.
• Prime Editing: Prime editing is a versatile and precise gene-editing technique that combines aspects of CRISPR and reverse transcriptase to introduce a wide range of genetic alterations, including insertions, deletions, and base substitutions. Prime editors use a guide RNA to target specific DNA sequences and reverse transcriptase to synthesize new DNA at the target site. This method provides high accuracy and flexibility, allowing for precise genetic modifications without the risk of off-target effects associated with traditional CRISPR/Cas9 methods.

Homology-Directed Repair (HDR):

It is a natural cellular mechanism for repairing double-strand breaks (DSBs) in DNA. This process uses a homologous sequence as a template to accurately repair the break. Leveraging the cell’s natural DNA repair mechanisms can improve the precision of gene integration.

Strategies to Promote HDR

Design of Donor Templates:

The length of the homology arms in the donor DNA template plays a significant role in HDR success. Arms typically range from 500 to 1000 base pairs, balancing efficient pairing with the target DNA and avoiding complications in synthesis or reduced integration efficiency.

Chemical Modulators:

Certain compounds, such as SCR7, target and inhibit non-homologous end joining (NHEJ), a DNA repair pathway that competes with HDR. By reducing NHEJ activity, these modulators can shift the repair mechanism preference towards HDR.

Genetic Modifications:

Alterations in the host cells, such as reducing the activity of NHEJ pathway components or increasing the expression of proteins involved in HDR, can improve the likelihood of HDR being used for DNA repair.

Use of Double-Strand Break Inducers:

Tools like CRISPR/Cas9 can create double-strand breaks (DSBs) at specific genomic locations, prompting the cell to repair the damage. The presence of a DSB increases the cell’s reliance on HDR, particularly when a donor template is provided, guiding precise genetic integration.

Gene Copy Number Control

Multicopy Plasmids:

Using plasmids that replicate to high copy numbers within the host cells can result in increased gene dosage. This method is particularly useful in transient expression systems, where plasmids are not integrated into the genome but still produce significant amounts of the desired protein.

Gene Amplification Systems:

Systems like dihydrofolate reductase (DHFR) gene amplification or the glutamine synthetase (GS) system are used to select cells with multiple copies of the integrated gene. These systems involve selective agents, such as methotrexate for DHFR or methionine sulfoximine for GS, to amplify the gene of interest along with the selection marker.

Targeted Multicopy Integration:

Advanced methods like site-specific recombination or CRISPR/Cas9-mediated integration can target multiple copies of the gene to specific genomic loci. This approach allows for controlled and uniform expression across cell populations.

Delivery Methods

Electroporation:

Electroporation uses electrical pulses to temporarily permeabilize the cell membrane, allowing DNA to enter the cell. Key parameters like voltage, pulse duration, and cell density can be adjusted to improve the efficiency of DNA delivery and subsequent gene integration. This method is widely applicable across various cell types, including hard-to-transfect cells.

Viral Vectors:

Viral vectors, including lentivirus and adeno-associated virus (AAV), are highly efficient for gene delivery. They can be optimized by adjusting viral titers, refining vector design, and tailoring infection conditions. Pseudotyping with different envelope proteins can extend their tropism, enabling effective transduction across a broader range of cell types. This versatility makes viral vectors a popular choice for stable gene integration.

Lipid Nanoparticles (LNPs):

LNPs serve as non-viral delivery systems, encapsulating nucleic acids such as plasmid DNA or CRISPR/Cas9 components. The effectiveness of LNPs depends on factors like lipid composition, particle size, and surface charge, which influence cellular uptake and endosomal escape. These properties can be optimized to maximize transfection efficiency and minimize cytotoxicity.

Microinjection:

Microinjection delivers DNA directly into cells or embryos using fine needles. While it is a labor-intensive and low-throughput technique, microinjection offers precise control over the quantity of DNA introduced. It is particularly useful for applications requiring targeted gene delivery to specific cells or tissues, ensuring accurate gene integration.

Magnetofection:

This technique involves using magnetic fields to concentrate magnetic nanoparticle-DNA complexes onto the cell surface, enhancing DNA uptake. Magnetofection offers high transfection efficiency with low cytotoxicity, making it suitable for delicate cell types. It provides a balance between effective gene delivery and maintaining cell viability.

Chemical Transfection Reagents:

Chemical reagents like calcium phosphate, polyethylenimine (PEI), and lipofectamine form complexes with DNA, facilitating its entry into cells. The efficiency of chemical transfection can be influenced by optimizing the ratios of reagent to DNA, incubation times, and specific cell culture conditions. These reagents are versatile and relatively easy to use, making them a common choice for both transient and stable gene expression studies.

Ensuring Stability of Integrated Genes

Ensuring the stability of integrated genes is essential for the consistent and long-term production of therapeutic antibodies. This stability is a fundamental aspect of developing stable cell lines, which are necessary for reliably expressing the desired gene over extended periods. Stable cell lines enable the production of therapeutic proteins at predictable and reproducible levels, maintaining product quality and efficacy.

Maintaining Stable Expression of Integrated Genes

Selection of Stable Cell Lines:

The development of stable cell lines begins with the integration of the desired gene into the host cell genome. This involves a series of steps to ensure that the gene remains stably expressed:

• Rigorous Screening: Following gene integration, cells undergo extensive screening to identify those with stable and consistent gene expression. This screening process involves evaluating the duration of gene expression, ensuring genetic integrity, and confirming the absence of mutations. These steps are crucial for selecting cell lines capable of sustaining high-level protein production without genetic deterioration.
• Clonal Isolation: Isolating and expanding individual clones helps create genetically uniform populations. This uniformity reduces variability in gene expression among the cells, ensuring that all cells in the population express the gene at similar levels. Homogeneity is vital for maintaining consistent product quality.

Key Aspects of Stable Cell Line Development:

• Consistent Gene Expression: Achieving consistent expression of the target gene is a primary objective. Consistent gene expression ensures that therapeutic proteins are produced at stable levels, which is critical for the quality and safety of the final product.
• Genetic and Epigenetic Stability: Genetic stability involves maintaining the integrity of the integrated gene, and preventing mutations or deletions. Epigenetic stability ensures that the gene remains transcriptionally active, free from silencing mechanisms like DNA methylation or histone modification.
• Scalability and Reproducibility: Stable cell lines must retain their stability and productivity as they scale from laboratory to industrial and commercial production levels. This scalability is supported by robust gene integration, which provides a consistent genetic foundation capable of withstanding various production conditions.
• Regulatory Compliance: Meeting regulatory requirements is a critical aspect of stable cell line development. Regulatory agencies require thorough documentation and validation of cell line stability to ensure consistent product quality and safety. This compliance is necessary for obtaining regulatory approval and commercializing therapeutic products.

ProteoGenix Services in Antibody Production

ProteoGenix has over 28 years of experience in the field of antibody production, making it a trusted leader in providing high-quality solutions for therapeutic development. ProteoGenix’s extensive experience, combined with cutting-edge technologies, enables tackle the complex challenges of gene integration and clone selection, crucial for producing therapeutic antibodies.

Overcoming Challenges of Gene Integration with Custom Gene Synthesis Service

ProteoGenix’s Custom Gene Synthesis service is expertly designed to address the challenges associated with gene integration, providing critical support for the development of therapeutic antibodies.

High-Quality Gene Sequence Engineering and Codon Optimization:

The service includes free codon optimization using ProteoGenix’s proprietary algorithm, which enhances gene expression by selecting the most efficient codons based on empirical data. This process is crucial for optimizing the expression of therapeutic genes in various host systems, thereby overcoming the common bottleneck of poor expression levels due to suboptimal codon usage.

Diverse Vector Library and Flexibility:

ProteoGenix provides a comprehensive library of cloning vectors and the flexibility to use custom vectors. This flexibility is essential for accommodating specific project requirements, such as vector backbone preferences or regulatory considerations, which can significantly impact the success of gene integration and subsequent expression.

Comprehensive Gene Libraries:

ProteoGenix maintains extensive gene libraries, including several dozen pre-synthesized human wild type genes. This resource not only reduces costs but also expedites the synthesis process, providing fast and reliable access to necessary cDNA sequences for various applications, including antibody drug discovery.

Learn more about our Custom Gene Synthesis service

Custom Cell Line Development Service: Overcoming Challenges with ProteoGenix

ProteoGenix’s Custom Cell Line Development Service is designed to address and overcome the critical challenges associated with optimal clone selection in antibody production. With a focus on early developability assessment, this service ensures that only the most stable, reactive, and effective antibody leads are selected for large-scale production, thus minimizing risks and optimizing costs.

Early Developability Assessment:

The service begins with an extensive early testing phase, where antibody leads are rigorously assessed for key characteristics such as aggregation, affinity, avidity, specificity, selectivity, and glycosylation profile. This thorough analysis allows for the identification of antibodies with the best potential for stable expression and therapeutic efficacy. By leveraging in silico analysis and recombinant antibody production, ProteoGenix can predict and measure these critical attributes, ensuring that only the most promising candidates proceed to the next stages of development.

Diverse Cell Line:

ProteoGenix offers a range of IP-free cell line options, including the highly versatile CHO and HEK cell lines, such as proprietary CHO-K1 and HEK293. These cell lines are preferred for their robust expression capabilities and flexibility allowing for optimal gene amplification and significantly higher production levels.

Innovative Technologies for Optimal Clone Selection:

To enhance the selection of optimal clones, ProteoGenix employs advanced technologies such as the Verified In-Situ Plate Seeding (VIPS) system. VIPS enables precise and efficient single-cell cloning, ensuring the selection of highly productive and stable clones. This technology significantly reduces the time and labor associated with traditional methods, streamlining the clone selection process and improving the overall success rate.

Learn more about our Custom Cell Line Development service

ProteoGenix’s services not only ensure the selection of optimal clones with stable and high-level expression but also support scalable and cost-effective production. This meticulous approach guarantees the development of therapeutic antibodies that meet the highest standards of quality and efficacy, ultimately facilitating successful clinical and commercial outcomes.

Partner with ProteoGenix for advanced custom cell line development services. Visit our dedicated service pages to learn more:

• Gene Synthesis Service
• Custom Cell Line Development services
• Stable Cell Lines For Monoclonal Antibody Production
• Recombinant Antibody Service

Choosing ProteoGenix means leveraging our extensive expertise, innovative technologies, and commitment to quality, all of which contribute to successful antibody production projects.

Book a call with our experts today to discuss your project needs!

References

Ausländer, Simon, et al. “Molecular Design of Viral Vectors for High Precision Genome Engineering.” Nucleic Acids Research, vol. 50, no. 9, 2022, pp. 4787–4800, doi:10.1093/nar/gkac252.

McDonnell, Susan, et al. “Challenges and Emerging Technologies in Biomanufacturing of Monoclonal Antibodies (mAbs).” IntechOpen, 17 Nov. 2022, doi:10.5772/intechopen.108565.

usländer, Simon, et al. “Genomic Barcoding for Clonal Diversity Monitoring and Control in Cell-Based Complex Antibody Production.” Scientific Reports, vol. 14, 2024, doi:10.1038/s41598-024-65323-7.